Payment overview · 2025
General Payments
$21,193.95
62 reported records · 14 companies
Healthcare provider profile · identity verified
Brian Patrick Miller, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · LA MESA, CA · NPI 1861411381
Verified facts
What the public records show
CMS Open Payments records show Brian Patrick Miller, M.D. received $21,193.95 in general payments during 2025 across 62 reported records.
Alkermes, Inc. accounted for 87.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Fanapt, Invega Sustenna, Lybalvi, Uzedy.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Lybalvi by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Spravato by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Uzedy by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18,571.87 | 87.6% | 26 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $1,739.05 | 8.2% | 13 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $334.43 | 1.6% | 7 | 2025 |
| H2-Pharma, LLC | Unresolved — no canonical attribution shown | $150.00 | 0.7% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $60.07 | 0.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.93 | 0.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.85 | 0.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.61 | 0.2% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $47.90 | 0.2% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $37.31 | 0.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.18 | 0.2% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $26.45 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.25 | 0.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.05 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,180.00 | 3 |
| Consulting Fee | $7,460.00 | 2 |
| Food and Beverage | $2,249.99 | 46 |
| Travel and Lodging | $2,153.96 | 10 |
| Honoraria | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $18,571.87 | 26 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $1,739.05 | 13 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $334.43 | 7 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $147.03 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $89.24 | 3 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SYMMETRY MODEL 8103 GENERATOR Normalized: vns therapy symmetry model 8103 generator |
Device | LivaNova USA, Inc. | $60.07 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.85 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $48.61 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $47.90 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 77 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UZEDY uzedy |
2025 | Uzedy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SPRAVATO open payments reported associated product |
CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254 |
Spravato · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | UZEDY open payments reported associated product |
CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226 |
Uzedy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clozapine | Clozapine | 479 | 21 |
| Olanzapine | Olanzapine | 363 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 238 | 25 |
| Benztropine Mesylate | Benztropine Mesylate | 234 | 28 |
| Divalproex Sodium | Divalproex Sodium | 177 | 18 |
| Lurasidone Hcl | Lurasidone Hcl | 151 | 13 |
| Haloperidol | Haloperidol | 133 | 15 |
| Trazodone Hcl | Trazodone Hcl | 127 | 21 |
| Gabapentin | Gabapentin | 121 | 18 |
| Olanzapine Odt | Olanzapine | 97 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 91 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 87 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 77 | suppressed |
| Aripiprazole | Aripiprazole | 73 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 66 | suppressed |
| Paliperidone Er | Paliperidone | 63 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 59 | suppressed |
| Risperidone | Risperidone | 59 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 58 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 56 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 52 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 51 | suppressed |
| Aristada | Aripiprazole Lauroxil | 49 | suppressed |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Fanapt | Iloperidone | 44 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 44 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | suppressed |
| Metformin Hcl | Metformin Hcl | 40 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Spravato | Esketamine Hcl | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 29 | 27 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 28 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 28 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 24 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Uzedy | Risperidone | 20 | suppressed |
| Clozapine Odt | Clozapine | 19 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21,193.95 · 62 records | Alkermes, Inc. | ABILIFY ASIMTUFII, ARISTADA, Auvelity, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA SUSTENNA, LYBALVI, NUCALA, SUBLOCADE, UZEDY, VNS THERAPY SYMMETRY MODEL 8103 GENERATOR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error